Granted Patent
B2
US 12,186,332 · App. 16/914,086 · Granted Jan 7, 2025
Methods for overcoming WNT/beta-catenin anti-cancer resistance in leukemia stem cells
Inventors:
Linheng Li (Kansas City, MO); John M. Perry (Olathe, KS); Fang Tao (Overland Park, KS); Xi C. He (Kansas City, MO); Anuradha Roy (Kansas City, MO); Scott J. Weir (Overland Park, KS); Tara Lin (Mission Hills, KS)
Assignees:
Stowers Institute for Medical Research; The Children's Mercy Hospital; University of Kansas
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides, inter alia, methods for treating cancers including leukemia using low doses of an anthracycline such as doxorubicin.
Claims (11)
1. A method for treating or ameliorating the effects of a cancer in a human subject comprising administering to the subject a first agent, which is daunorubicin or pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a second agent, which is a chemotherapeutic,
wherein daunorubicin is administered at 6.75 mg/m 2 daily, for 5 consecutive days.
2. The method according to claim 1 , wherein the second agent is selected from nelarabine, dexamethasone, and combinations thereof.
3. The method according to claim 1 , wherein the first and second agents are co-administered.
4. The method according to claim 1 , wherein the first agent is administered prior to the second agent.
5. The method according to claim 1 , wherein the second agent is administered prior to the first agent.
6. The method according to claim 1 , wherein the administration of the first and second agents to the subject provides a synergistic effect in the treatment of the cancer.
7. The method according to claim 1 , wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, colon cancer, esophageal cancer, endometrial cancer, gastric cancer, glioblastoma, head and neck cancer, hepatocellular carcinoma, leukemia, lung cancer, lymphoma, melanoma, multiple myeloma, neuroblastoma, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cell carcinoma, rhabdoid cancer, sarcomas, and urinary track cancer.
8. The method according to claim 1 , wherein the cancer is selected from the group consisting of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL).
9. The method according to claim 1 , wherein the cancer in the subject is relapsed or refractory.
10. The method according to claim 1 , wherein the cancer in the subject is chemoresistant.
Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 54126 FRAME 546. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Recorded Jul 8, 2024
From: PERRY, JOHN M.; TAO, FANG
To: THE CHILDREN'S MERCY HOSPITAL
Reel/Frame 068220/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 22, 2020
From: ROY, ANURADHA; WEIR, SCOTT J.; LIN, TARA
To: UNIVERSITY OF KANSAS
Reel/Frame 054725/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 21, 2020
From: PERRY, JOHN M.; TAO, FANG
To: CHILDREN'S MERCY HOSPITAL KANSAS CITY
Reel/Frame 054126/0546 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 21, 2020
From: LI, LINHENG; HE, XI C.
To: STOWERS INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 054161/0015 →
Continuity (2)
Provisional Application
62867780
· Jun 27, 2019
References Cited (108)
US 20150272992A1
· Prockop
· 2015
[cited by examiner]
US 20190269629A1
· Podestá
· 2019
[cited by examiner]
US 20200171165A1
· Schnitzer
· 2020
[cited by examiner]
US 20220105114A1
· Kasi
· 2022
[cited by examiner]
Hsu et al. (2015) Oncotarget 6(42): 44134-44150.
[cited by examiner]
Kwak et al. (2017) Journal of Controlled Release 267: 203-213.
[cited by examiner]
Manso et al. (2013) Clin Transl Oncol 15: 467-471.
[cited by examiner]
Rahman et al. (1986) Cancer Chemother Pharmacol 16: 22-27.
[cited by examiner]
Doxorubicin Hydrochloride Label/Package Insert, 2013, 26 pages.
[cited by examiner]
Doxorubicin Hydrochloride Label/Package Insert, 2019, 26 pages.
[cited by examiner]
Daunorubicin Label (Hikma Pharmaceuticals USA Inc, revised May 2015); 10 pages.
[cited by examiner]
Xu, C. et al. beta-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res 73, 3181-3189 (2013).
[cited by applicant]
Cancer Genome Atlas Research, N. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
[cited by applicant]
Guezguez, B. et al. GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia. Cancer Cell 29, 61-74 (2016).
[cited by applicant]
Al-Dhfyan, A., Alhoshani, A. & Korashy, H. M. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and beta-Catenin and Akt activation. Mol Cancer 16,…
[cited by applicant]
Brown, J. B. et al. Epithelial phosphatidylinositol-3-kinase signaling is required for beta-catenin activation and host defense against Citrobacter rodentium infection. Infect Immun 79, 1863-1872 (2011).
[cited by applicant]
Lee, G. et al. Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 139, 869-881, 881 e861-869 (2010).
[cited by applicant]
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168, 707-723 (2017).
[cited by applicant]
Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231-235 (2015).
[cited by applicant]
Spranger, S. & Gajewski, T. F. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer 18, 139-147 (2018).
[cited by applicant]
Galluzzi, L., Buque, A., Kepp, 0., Zitvogel, L. & Kroemer, G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell 28, 690-714 (2015).
[cited by applicant]
Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202, 1691-1701 (2005).
[cited by applicant]
Rabbani, A., Finn, R. M. & Ausio, J. The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays 27, 50-56 (2005).
[cited by applicant]
Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57, 727-741 (1999).
[cited by applicant]
Gothert, J. R. et al. In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood 105, 2724-2732 (2005).
[cited by applicant]
Barker, N. & Clevers, H. Catenins, Wnt signaling and cancer. Bioessays 22, 961-965 (2000).
[cited by applicant]
Hsu, J. M. et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nature communications 9, 1908 (2018).
[cited by applicant]
Malta, T. M. et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173, 338-354 e315 (2018).
[cited by applicant]
Jinesh, G. G., Manyam, G. C., Mmeje, C. 0., Baggerly, K. A. & Kamat, A. M. Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Scientific reports 7…
[cited by applicant]
Chen, G. Y., Tang, J., Zheng, P. & Liu, Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323, 1722-1725 (2009).
[cited by applicant]
Tran, T. H. et al. Long circulating self-assembled nanoparticles from cholesterol-containing brush-like block copolymers for improved drug delivery to tumors. Biomacromolecules 15, 4363-4375 (2014).
[cited by applicant]
Hong, D. et al. Initiating and cancer-propagating cells in TEL-AML 1-associated childhood leukemia. Science 319, 336-339 (2008).
[cited by applicant]
Castor, A. et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 11, 630-637 (2005).
[cited by applicant]
Kong, Y. et al. CD34+CD38+CD19+ as well as CD34+CD38−CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 22, 1207-1213 (2008).
[cited by applicant]
Wilson, K. et al. Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34+CD38lowCD19+ in B-lineage childhood acute lymphoblastic leukemia. Haematologica 95, 679-68…
[cited by applicant]
Eguchi, M., Eguchi-Ishimae, M. & Ishii, E. [Recent progress in leukemic stem cell research for childhood leukemia]. Rinsho Ketsueki 56, 1871-1881 (2015).
[cited by applicant]
Kikushige, Y. et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7, 708-717 (2010).
[cited by applicant]
Jan, M. et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A 108, 5009-5014 (2011).
[cited by applicant]
Weinberg, R. A. The biology of cancer. Second edition. edn, (2014).
[cited by applicant]
Nitiss, J. L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9, 338-350 (2009).
[cited by applicant]
Anderson, A. C. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2, 393-398 (2014).
[cited by applicant]
Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity 44, 989-1004 (2016).
[cited by applicant]
Lesche, R. et al. Cre/IoxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32, 148-149 (2002).
[cited by applicant]
Harada, N. et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. Embo J 18, 5931-5942 (1999).
[cited by applicant]
Hu, Y. & Smyth, G. K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. Journal of immunological methods 347, 70-78 (2009).
[cited by applicant]
Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H. & Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer chemotherapy reports. Part 1 50,…
[cited by applicant]
Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14, R36 (2013).
[cited by applicant]
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166-169 (2015).
[cited by applicant]
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
[cited by applicant]
Miao, Y. et al. Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells. Cell 177, 1172-1186 e1114, doi:10.1016/j.ce11.2019.03.025 (2019).
[cited by applicant]
Kuttesch, J. F., Jr. Multidrug resistance in pediatric oncology. Invest New Drugs 14, 55-67 (1996).
[cited by applicant]
Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306-313 (2012).
[cited by applicant]
Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275-291 (2014).
[cited by applicant]
Dick, J. E. Stem cell concepts renew cancer research. Blood 112, 4793-4807 (2008).
[cited by applicant]
Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17, 1086-1093 (2011).
[cited by applicant]
Greaves, M. Darwinian medicine: a case for cancer. Nat Rev Cancer 7, 213-221 (2007).
[cited by applicant]
Greaves, M. Cancer stem cells renew their impact. Nat Med 17, 1046-1048 (2011).
[cited by applicant]
Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012).
[cited by applicant]
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
[cited by applicant]
Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13, 714-726 (2013).
[cited by applicant]
Cleary, M. L. Regulating the leukemia stem cell. Best practice & research. Clinical haematology 22, 483-487 (2009).
[cited by applicant]
Peng, W. et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer discovery 6, 202-216 (2016).
[cited by applicant]
Fruman, D. A. et al. The PI3K Pathway in Human Disease. Cell 170, 605-635 (2017).
[cited by applicant]
Ciraolo, E., Morello, F. & Hirsch, E. Present and future of PI3K pathway inhibition in cancer: perspectives and imitations. Current medicinal chemistry 18, 2674-2685 (2011).
[cited by applicant]
Cully, M., You, H., Levine, A. J. & Mak, T. W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6, 184-192 (2006).
[cited by applicant]
Fruman, D. A. & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nature reviews. Drug discovery 13, 140-156 (2014).
[cited by applicant]
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. & Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature reviews. Drug discovery 4, 988-1004 (2005).
[cited by applicant]
Koren, S. & Bentires-Alj, M. Tackling Resistance to PI3K Inhibition by Targeting the Epigenome. Cancer Cell 31, 616-618 (2017).
[cited by applicant]
Thorpe, L. M., Yuzugullu, H. & Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15, 7-24 (2014).
[cited by applicant]
Gutierrez, A. et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647-650 (2009).
[cited by applicant]
Hogan, L. E. et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 118, 5218-5226 (2011).
[cited by applicant]
Bhatla, T. et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 119, 5201-5210 (2012).
[cited by applicant]
Bolouri, H. et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med 24, 103-112 (2018).
[cited by applicant]
Griffiths, E. A. et al. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leukemia & lymphoma 51, 1711-1719 (2010).
[cited by applicant]
Dandekar, S. et al. Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. Br J Haematol 167, 87-99 (2014).
[cited by applicant]
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
[cited by applicant]
Huang, J., Nguyen-McCarty, M., Hexner, E. 0., Danet-Desnoyers, G. & Klein, P. S. Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways. Nat Med 18, 1778-1785 (2012).
[cited by applicant]
Korkaya, H. et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 7, e1000121 (2009).
[cited by applicant]
Huang, J. et al. Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. J Clin Invest 119, 3519-3529 (2009).
[cited by applicant]
Conley, S. J. et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109, 2784-2789 (2012).
[cited by applicant]
He, X. C. et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 39, 189-198 (2007).
[cited by applicant]
Perry, J. M. et al. Cooperation between both Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev 25, 1928-1942 (2011).
[cited by applicant]
Knapp, D. J. et al. Distinct signaling programs control human hematopoietic stem cell survival and proliferation. Blood 129, 307-318 (2017).
[cited by applicant]
Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328-333 (2014).
[cited by applicant]
Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
[cited by applicant]
Nguyen, L. V., Vanner, R., Dirks, P. & Eaves, C. J. Cancer stem cells: an evolving concept. Nat Rev Cancer 12, 133-143 (2012).
[cited by applicant]
Clevers, H. The cancer stem cell: premises, promises and challenges. Nat Med 17, 313-319 (2011).
[cited by applicant]
Zhou, H. et al. Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant plast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia (20…
[cited by applicant]
Kurtova, A. V. et al. Blocking PGE-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature (2014).
[cited by applicant]
Heidel, F. H. et al. Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 10, 412-424 (2012).
[cited by applicant]
Zhao, C. et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12, 528-541 (2007).
[cited by applicant]
Toska, E. et al. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science 355, 1324-1330 (2017).
[cited by applicant]
Tenbaum, S. P. et al. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 18, 892-901 (2012).
[cited by applicant]
Kaveri, D. et al. beta-Catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL. Blood 122, 694-704 (2013).
[cited by applicant]
Guo, W. et al. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 453, 529-533 (2008).
[cited by applicant]
Roderick, J. E. et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 123, 1040-1050 (2014).
[cited by applicant]
Schubbert, S. et al. Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia. Cancer Res 74, 7048-7059 (2014).
[cited by applicant]
Dail, M. et al. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature 513, 512-516 (2014).
[cited by applicant]
Huang, W., Chang, H. Y., Fei, T., Wu, H. & Chen, Y. G. GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene 26, 2471-2482 (2007).
[cited by applicant]
Lechman, E. R. et al. Attenuation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cell 11, 799-811 (2012).
[cited by applicant]